MOSCOW (MRC) -- Evonik Corporation’s High Performance Polymers Business Line has announced a distribution agreement with chemicals, plastics and composites distributor Nexeo Solutions for VESTAMID, VESTAMID Care, TROGAMID and TROGAMID Care product lines used in medical device applications, reported the company on its site.
"We are very excited about this alliance with Nexeo Solutions," said Sabine Fleming, business development manager of Evonik Corporation’s High Performance Polymers Business Line. "Nexeo Solutions has a dedicated healthcare team with significant expertise in the distribution of plastics and chemicals used for medical devices. This alliance will offer Evonik Corporation broader medical market exposure and our customers more supply chain flexibility for our specialty high performance polymers. Our customers will benefit from Nexeo Solution’s excellent distribution service and market presence."
TROGAMID is a key ingredient for stopcocks, valves used to restrict or isolate the flow of liquids or gases.
Evonik Corporation’s VESTAMID and TROGAMID are specialty polymers characterized by excellent chemical resistance, biocompatibility, durability.
As MRC wrote previously, Evonik Industries, the German specialty chemicals company, has announced a significant expansion of its Jurong Island, Singapore oil additives plant, to be completed in early 2015. With ongoing improvement and debottlenecking projects scheduled to be finalized during the first half of 2014, these optimizations and the planned expansion will nearly double the capacity of the oil additives plant in Singapore.
Nexeo Solutions is the largest global chemical, plastics and composites distributor and environmental services with a centralized business model. As a private company employing more than 2300 employees with operations across North America, Europe and Asia, Nexeo Solutions is a leading distributor of chemicals, plastics, composites and environmental services.
Evonik Industries is an industrial corporation in Germany and one of the world's leading specialty chemicals companies. Company's specialty chemicals activities focus on high-growth megatrends, especially, health, nutrition, resource efficiency, and globalization, and on entering attractive future-oriented markets. In 2012 Evonik generated sales of EUR13.6 billion and an operating result (adjusted EBITDA) of EUR2.6 billion.
MRC